BACKGROUND: A blood-based biomarker of Alzheimer's disease (AD) would be superior to cerebrospinal fluid (CSF) and neuroimaging measures in terms of cost, invasiveness, and feasibility for repeated measures. We previously reported that blood ceramides varied in relation to timing of memory impairment in a population-based study. The present objective was to examine whether plasma ceramides varied by AD severity in a well-characterized clinic sample and were associated with cognitive decline and hippocampal volume loss over 1 year. METHODS: Participants included 25 normal controls (NC), 17 amnestic Mild Cognitive Impairment (MCI), and 21 early probable AD. A thorough neuropsychological battery and neuroimaging with hippocampal volume determination were conducted at baseline and 1 year later. Plasma ceramides were assayed at baseline using high performance liquid chromatography coupled electrospray ionization tandem mass spectrometry. RESULTS: Although all saturated ceramides were lower in MCI compared with AD at baseline, ceramides C22:0 and C24:0 were significantly lower in the MCI group compared with both NC and AD groups (P < .01). Ceramide levels did not differ (P > .05) in AD versus NC. There were no cross-sectional associations between ceramides C22:0 and C24:0 and either cognitive performance or hippocampal volume among any group. However, among the MCI group, higher baseline ceramide C22:0 and C24:0 levels were predictive of cognitive decline and hippocampal volume loss 1 year later. CONCLUSION: Results suggest that very long-chain plasma ceramides C22:0 and C24:0 are altered in MCI and predict memory loss and right hippocampal volume loss among subjects with MCI. These plasma ceramides may be early indicators of AD progression. Copyright 2010 The Alzheimer
BACKGROUND: A blood-based biomarker of Alzheimer's disease (AD) would be superior to cerebrospinal fluid (CSF) and neuroimaging measures in terms of cost, invasiveness, and feasibility for repeated measures. We previously reported that blood ceramides varied in relation to timing of memory impairment in a population-based study. The present objective was to examine whether plasma ceramides varied by AD severity in a well-characterized clinic sample and were associated with cognitive decline and hippocampal volume loss over 1 year. METHODS:Participants included 25 normal controls (NC), 17 amnestic Mild Cognitive Impairment (MCI), and 21 early probable AD. A thorough neuropsychological battery and neuroimaging with hippocampal volume determination were conducted at baseline and 1 year later. Plasma ceramides were assayed at baseline using high performance liquid chromatography coupled electrospray ionization tandem mass spectrometry. RESULTS: Although all saturated ceramides were lower in MCI compared with AD at baseline, ceramides C22:0 and C24:0 were significantly lower in the MCI group compared with both NC and AD groups (P < .01). Ceramide levels did not differ (P > .05) in AD versus NC. There were no cross-sectional associations between ceramides C22:0 and C24:0 and either cognitive performance or hippocampal volume among any group. However, among the MCI group, higher baseline ceramide C22:0 and C24:0 levels were predictive of cognitive decline and hippocampal volume loss 1 year later. CONCLUSION: Results suggest that very long-chain plasma ceramides C22:0 and C24:0 are altered in MCI and predict memory loss and right hippocampal volume loss among subjects with MCI. These plasma ceramides may be early indicators of AD progression. Copyright 2010 The Alzheimer
Authors: Lucie Kalvodova; Nicoletta Kahya; Petra Schwille; Robert Ehehalt; Paul Verkade; David Drechsel; Kai Simons Journal: J Biol Chem Date: 2005-08-22 Impact factor: 5.157
Authors: Cleusa P Ferri; Martin Prince; Carol Brayne; Henry Brodaty; Laura Fratiglioni; Mary Ganguli; Kathleen Hall; Kazuo Hasegawa; Hugh Hendrie; Yueqin Huang; Anthony Jorm; Colin Mathers; Paulo R Menezes; Elizabeth Rimmer; Marcia Scazufca Journal: Lancet Date: 2005-12-17 Impact factor: 79.321
Authors: H Satoi; H Tomimoto; R Ohtani; T Kitano; T Kondo; M Watanabe; N Oka; I Akiguchi; S Furuya; Y Hirabayashi; T Okazaki Journal: Neuroscience Date: 2005 Impact factor: 3.590
Authors: V V R Bandaru; J C McArthur; N Sacktor; R G Cutler; E L Knapp; M P Mattson; N J Haughey Journal: Neurology Date: 2007-05-01 Impact factor: 9.910
Authors: Michelle M Mielke; Veera Venkata Ratnam Bandaru; Norman J Haughey; Peter V Rabins; Constantine G Lyketsos; Michelle C Carlson Journal: Neurobiol Aging Date: 2008-05-05 Impact factor: 4.673
Authors: Joanna M Cordy; Ishrut Hussain; Colin Dingwall; Nigel M Hooper; Anthony J Turner Journal: Proc Natl Acad Sci U S A Date: 2003-09-22 Impact factor: 11.205
Authors: M M Mielke; N A Kozauer; K C G Chan; M George; J Toroney; M Zerrate; K Bandeen-Roche; M-C Wang; P Vanzijl; J J Pekar; S Mori; C G Lyketsos; M Albert Journal: Neuroimage Date: 2009-02-05 Impact factor: 6.556
Authors: Michelle M Mielke; Ozioma C Okonkwo; Kenichi Oishi; Susumu Mori; Sarah Tighe; Michael I Miller; Can Ceritoglu; Timothy Brown; Marilyn Albert; Constantine G Lyketsos Journal: Alzheimers Dement Date: 2012 Impact factor: 21.566
Authors: Michelle M Mielke; Veera Vankata Ratnam Bandaru; Norman J Haughey; Jin Xia; Linda P Fried; Sevil Yasar; Marilyn Albert; Vijay Varma; Greg Harris; Eric B Schneider; Peter V Rabins; Karen Bandeen-Roche; Constantine G Lyketsos; Michelle C Carlson Journal: Neurology Date: 2012-07-18 Impact factor: 9.910
Authors: Michelle M Mielke; Norman J Haughey; Veera V R Bandaru; Henrik Zetterberg; Kaj Blennow; Ulf Andreasson; Sterling C Johnson; Carey E Gleason; Hanna M Blazel; Luigi Puglielli; Mark A Sager; Sanjay Asthana; Cynthia M Carlsson Journal: Neurobiol Aging Date: 2014-05-27 Impact factor: 4.673